ORBIMED ADVISORS LLC

Q2 2026 13F-HR Holdings

Location
New York, NY
Holdings as of
6/30/2026
Date filed
8/14/2026
Form type
13F-HR
Num holdings
129
Total value ($000)
$5,396,780
Net value change ($000)
+351,416 (7.0%)
New positions
32
Sold out positions
21
Turnover %
17.9%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 5/15/2026 Next filing: — SEC filing

Snapshot: Change Analysis

Compared to Q1 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
EWTX 141,684 29.0%
LLY 91,531 42.0%
MBX 80,675 74.3%
UNH 66,958 NEW
Ascendis Pharma AS 65,201 NEW
HUM 65,184 NEW
ODYSSEY THERAPEUTICS INC 56,152 NEW
ARQT 53,541 NEW
COGT 52,668 424.8%
QURE 48,327 138.4%
Top Reduces (Value $000, Stocks/ETFs)
MYGN -122,875 -100.0%
BSX -86,174 -57.7%
PFE -54,658 -100.0%
DHR -50,396 -100.0%
CMPX -47,182 -58.6%
IRON -42,109 -61.7%
ASND -41,624 -100.0%
ALNY -34,256 -87.0%
ISRG -33,415 -34.7%
SION -29,113 -20.6%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 117,379 (2.2% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type